GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2007

CytoDyn Selects Waisman Facility to Manufacture DNA-based Preflu Vaccine

  • CytoDyn chose the Waisman Clinical BioManufacturing Facility at the University of Wisconsin at Madison to manufacture its DNA-based preflu vaccine. The company says the product provides an alternative approach to immunization that could make flu vaccines for the seasonal flu and bird flu more effective.

    The vaccine uses DNA technology to implant a false memory of previous exposure to the flu virus, including the inactivated virus contained in standard vaccines.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »